- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$321.37

Market cap

$82.49B

P/E Ratio

25.11

Dividend/share

N/A

EPS

$12.8

Enterprise value

$74.15B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather

The EPS has surged by 52% year-on-year and by 2.6% since the previous quarter

Vertex Pharmaceuticals's net income has surged by 50% YoY and by 2.5% QoQ

The price to earnings (P/E) is 46% less than the 5-year quarterly average of 46.2 but 3.8% more than the last 4 quarters average of 24.2

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

256.69M

Market cap

$82.49B

Enterprise value

$74.15B

Price to earnings (P/E)

25.11

Price to book (P/B)

6.33

Price to sales (P/S)

9.47

EV/EBIT

18.15

EV/EBITDA

17.53

EV/Sales

8.52

Revenue

$8.7B

EBIT

$4.08B

EBITDA

$4.23B

Free cash flow

$3.81B

Per share
Balance sheet
Liquidity

EPS

$12.8

Free cash flow per share

$14.87

Book value per share

$50.81

Revenue per share

$33.92

TBVPS

$58.59

Total assets

$16.71B

Total liabilities

$3.68B

Debt

$824.6M

Equity

$13.03B

Working capital

$9.66B

Debt to equity

0.06

Current ratio

4.7

Quick ratio

4.28

Net debt/EBITDA

-1.97

Margins
Efficiency
Dividend

EBITDA margin

48.6%

Gross margin

88%

Net margin

37.6%

Operating margin

47%

Return on assets

21.8%

Return on equity

28.5%

Return on invested capital

103.5%

Return on capital employed

29%

Return on sales

46.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

Intraday

0.19%

1 week

2.68%

1 month

3.66%

1 year

57.19%

YTD

46.34%

QTD

10.99%

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$8.7B

Gross profit

$7.66B

Operating income

$4.09B

Net income

$3.27B

Gross margin

88%

Net margin

37.6%

The operating income has surged by 54% year-on-year

Vertex Pharmaceuticals's net income has surged by 50% YoY and by 2.5% QoQ

The operating margin has increased by 26% YoY but it has decreased by 2.5% QoQ

VRTX's net margin is up by 23% YoY

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

25.11

P/B

6.33

P/S

9.47

EV/EBIT

18.15

EV/EBITDA

17.53

EV/Sales

8.52

The EPS has surged by 52% year-on-year and by 2.6% since the previous quarter

The price to earnings (P/E) is 46% less than the 5-year quarterly average of 46.2 but 3.8% more than the last 4 quarters average of 24.2

The equity has grown by 37% YoY and by 9% from the previous quarter

The stock's price to book (P/B) is 33% less than its 5-year quarterly average of 9.5 but 9% more than its last 4 quarters average of 5.8

VRTX's revenue is up by 22% YoY and by 4.2% QoQ

The price to sales (P/S) is 20% less than the 5-year quarterly average of 11.9 but 14% more than the last 4 quarters average of 8.3

How efficient is Vertex Pharmaceuticals business performance

The return on invested capital rose by 33% year-on-year

VRTX's return on assets is up by 22% year-on-year but it is down by 4.8% since the previous quarter

The return on sales has increased by 19% year-on-year

The return on equity has grown by 19% year-on-year but it has declined by 5% since the previous quarter

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's total assets has increased by 32% YoY and by 7% QoQ

The total liabilities has increased by 19% YoY

VRTX's debt is 94% lower than its equity

The equity has grown by 37% YoY and by 9% from the previous quarter

The debt to equity fell by 33% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.